Search
Novo Nordisk A/S
NVOAdd to Watchlist
43.190USD
-0.325-0.75%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
152.42BMarket Cap
10.10P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Novo Nordisk A/S is 6.86, ranking 123 out of 157 in the Pharmaceuticals industry. The average price target is 53.39, with a high of 90.39 and a low of 41.90.
Analyst Rating
Based on
14
analysts
Hold
Current Rating
49.612
Target Price
+14.00%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
175
Total
6
Median
8
Average
Company name
Ratings
Analysts
Novo Nordisk A/S
NVO
14
Biogen Inc
BIIB
38
Amgen Inc
AMGN
38
Eli Lilly and Co
LLY
35
AbbVie Inc
ABBV
34
Vertex Pharmaceuticals Inc
VRTX
34
1
2
3
...
35
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Novo Nordisk A/S's expected revenue for the next quarter?
Novo Nordisk A/S's expected revenue is 11.27B.
What is Novo Nordisk A/S's price target?
Analysts forecast that Novo Nordisk A/S's price target is USD 53.39, with the highest forecast at USD 90.39 and the lowest forecast at USD 41.90.
How have Novo Nordisk A/SNVO's recent earnings per share performed?
The market expectation was USD 1.71, while Novo Nordisk A/SNVO's earnings per share (EPS) for the previous quarter was USD 0.94. EPS for the next quarter is expected at USD 0.82.
What is the analyst rating for Novo Nordisk A/S?
Based on the ratings of Novo Nordisk A/S's stock from 14 analysts, most analysts support a signal_hold trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as signal_hold. Please note that this is not trading advice. You still need to conduct your own analysis.
